Royalty Pharma Plc · NASDAQ:RPRX

Royalty Pharma — Investor Presentation (November 2025)

7 slides from Royalty Pharma's investor presentation, November 2025

  1. Slide 1: Royalty acquisition

    royalty acquisition November 2025

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete o

  3. Slide 3: Key messages

    3 Key messages 1 2 3 Amvuttra for ATTR amyloidosis Compelling patient benefit Significant market opportunity Alnylam’s Amvuttra, an approved Progressive, debilitating and fatal ~30,000 hATTR-PN and >300,000 RNAi for cardiomyopathy of disease caused by misfolded TTR ATTR-CM patients globally(3) trans

  4. Slide 4: Acquired royalty on Alnylam's Amvuttra for ATTR amyloidosis

    4 Acquired royalty on Alnylam’s Amvuttra for ATTR amyloidosis Amvuttra – expanding the ATTR amyloidosis market Amvuttra reported and consensus sales(4) ($ in billions) • Acquired Blackstone’s royalty on Alnylam’s Amvuttra for ATTR $10 amyloidosis for $310m 8.4 7.7 • Entitled to 1% royalty on worldwi

  5. Slide 5: The ATTR amyloidosis market consists of five approved therapies

    5 The ATTR amyloidosis market consists of five approved therapies Amvuttra well positioned for growth given expanded label, convenient dosing and favorable reimbursement Silencer Stabilizer Marketer CM: March 2025 CM: n/a(1) CM: May 2019 Approval PN: August 2018 CM: Nov 2024 PN: June 2022 PN: Dec 20

  6. Slide 6: Rapid growth driven by new therapies with compelling patient benefit

    6 Rapid growth driven by new therapies with compelling patient benefit Amvuttra U.S. approval in ATTR-CM expected to drive strong 2025+ growth with ex-U.S. expansion to follow hATTR-PN market sales by product(1) ATTR-CM market sales by product(1) ($ in billions) ($ in billions) ~34% ~64% CAGR CAGR $

  7. Slide 7: ATTR-CM approval in March 2025 a significant growth opportunity

    7 ATTR-CM approval in March 2025 a significant growth opportunity Royalty Pharma analysis supports increasing duration of treatment overtime as patients are diagnosed earlier (1) (1) (1) ~18,000 ~20,000 ~80% 3 key patient (annual (annual patients) patients globally) (patients globally) asdfsapatient

Royalty Pharma — Investor Presentation (November 2025) on 6ix